Steel Authority of India shares are banned from F&O trading on Thursday, 17 November 2025.

Stocks to Watch:

Tata Motors Passenger Vehicles (TMPV) reported a 2,110% surge in net profit to Rs 76,170 crore in Q2 FY26, compared with Rs 3,446 crore in Q2 FY25, led by exceptional gains of Rs 82,616 crore from the disposal of discontinued operations. Revenue from operations declined 13.4% YoY to Rs 71,714 crore.

Kotak Mahindra Bank announced that its board is scheduled to meet on Friday, 21 November 2025, to consider a proposal for the subdivision (split) of its existing fully paid-up equity shares having a face value of Rs 5 each.

Narayana Hrudayalaya reported a consolidated net profit of Rs 258 crore in Q2 FY26, up 30% year-on-year. Revenue rose 20% YoY to Rs 1,644 crore. EBITDA increased 30% to Rs 403 crore, and operating margin improved to 24.5% from 22.6% in Q2 FY25.

Max Healthcare Institute posted a net profit of Rs 491 crore for Q2 FY26, up 74.3% from Rs 282 crore in Q2 FY25. Revenue stood at Rs 2,135 crore, higher by 25% YoY.

Oil India reported a net profit of Rs 1,044 crore for the September quarter, up 28% quarter-on-quarter from Rs 813.5 crore in the previous quarter. Revenue increased 8.9% QoQ to Rs 5,456 crore from Rs 5,012 crore.

TruAlt Bioenergy signed an MoU with the Andhra Pradesh Economic Development Board to set up an integrated ethanol-to-SAF manufacturing facility with an investment of about Rs 2,250 crore.

IRB Infrastructure Developers received the Letter of Award from NHAI for the TOT-17 bundle covering 366 km of the Lucknow-Ayodhya-Gorakhpur corridor on NH-27 and part of the Lucknow-Varanasi corridor on NH-731 for a 20-year revenue-linked concession.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride tablets. Diltiazem Hydrochloride tablets are indicated for the management of chronic stable angina.

Lupin announced that the United States Food and Drug Administration (USFDA) has completed a product-specific pre-approval inspection at the company’s Unit-1 oral solid dosage manufacturing facility in Nagpur. The inspection was carried out from November 10 to 14 and concluded with zero 483 observations.

Websol Energy System, through subsidiary Websol Renewables, signed an MoU with the Andhra Pradesh Economic Development Board to develop a 4 GW integrated solar cell and module manufacturing facility in Andhra Pradesh.